Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

CAR T-Cell Therapy for Multiple Myeloma: What Community Oncologists Need to Know

November 10th 2020

The emergence of cellular-based therapies represents a major opportunity to improve outcomes in the heavily pretreated and refractory myeloma population.

Dr. Popat on Unmet Needs in Triple-Class Refractory Multiple Myeloma

November 5th 2020

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses unmet needs in triple-class refractory multiple myeloma.

Dr. Lonial on the Advantage of Targeting BCMA in Multiple Myeloma

November 4th 2020

Sagar Lonial, MD, FACP, discusses the advantage of targeting BCMA in multiple myeloma.

BCMA-Targeting Drugs Take Center Stage in Myeloma

November 4th 2020

The treatment landscape for multiple myeloma is poised to enter a new era of innovation with the development of therapies that target B-cell maturation antigen, which is highly expressed on plasma and MM cells.

Dr. Lonial on the Role of BCMA in Multiple Myeloma

November 2nd 2020

Sagar Lonial, MD, FACP, discusses the role of BCMA as a target in multiple myeloma.

High Response Rates Heighten Excitement With CAR T-Cell Therapy in Multiple Myeloma

October 30th 2020

Faiz Anwer, MD, discusses the growing role of CAR T-cell therapy in multiple myeloma and areas of unmet need.

MRD Negativity Remains Key Goal in Frontline Myeloma Treatment

October 27th 2020

Andrew Kin, MD, discusses the shift in goals for frontline treatment in multiple myeloma.

Dr. Galligan on Unmet Needs in High-Risk Multiple Myeloma

October 27th 2020

Derek C. Galligan, MD, discusses unmet needs in high-risk multiple myeloma.

Dr. Nagle on the Evolution of Daratumumab Administration in Multiple Myeloma

October 22nd 2020

Sarah Nagle, MD, discusses the evolution of daratumumab administration in multiple myeloma.

FDA Approval Insights: Daratumumab / Carfilzomib / Dexamethasone in Myeloma

October 22nd 2020

In our exclusive interview, Saad Z. Usmani, MD, FACP, discusses the FDA approval of daratumumab, carfilzomib, and dexamethasone in relapsed/refractory multiple myeloma.

Maintenance Daratumumab Improves PFS in Newly Diagnosed Transplant-Eligible Myeloma

October 22nd 2020

Single-agent daratumumab as maintenance therapy improved progression-free survival compared with observation in patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant.

Hari Reviews Recent Data in Relapsed/Refectory Multiple Myeloma

October 22nd 2020

Parameswaran Hari, MD, MRCP, discusses key data that has read out in relapsed/refractory multiple myeloma, exciting agents generating excitement, and the role of minimal residual disease.

Dr. Galligan on Transplant Eligibility and Subsequent Treatments in Multiple Myeloma

October 20th 2020

Derek C. Galligan, MD, discusses transplant eligibility in determining subsequent treatment for patients with multiple myeloma.

Dr. Nagle on Sequencing Challenges in Multiple Myeloma

October 19th 2020

Sarah Nagle, MD, discusses sequencing challenges in multiple myeloma.

NICE Recommends Isatuximab Plus Pomalidomide/Dexamethasone for Relapsed/Refractory Myeloma

October 16th 2020

The United Kingdom’s National Institute for Health and Care Excellence has recommended isatuximab-irfc in combination with pomalidomide and dexamethasone as a treatment option for select patients with relapsed/refractory multiple myeloma.

Dr. Silbermann on the CASTOR Trial in Relapsed/Refractory Myeloma

October 16th 2020

Rebecca Silbermann, MD, MMS, discusses the phase 3 CASTOR trial in relapsed/refractory multiple myeloma.

Quad Therapy Induces Deep Responses in Black Patients With Multiple Myeloma

October 16th 2020

Data from a subgroup analysis of the phase 2 GRIFFIN study demonstrated that adding daratumumab to lenalidomide, bortezomib, and dexamethasone improved depth of response, stringent complete response, and minimal residual disease negativity, in Black patients with newly diagnosed multiple myeloma.

Innovative Approaches Augment Sequencing in Prolific Multiple Myeloma Armamentarium

October 14th 2020

Sarah Nagle, MD, spotlights the critical role of targeted therapy in multiple myeloma.

Dr. Galligan the Utility of Up-front High-Intensity Therapy in Multiple Myeloma

October 13th 2020

Derek C. Galligan, MD, discusses the utility of up-front high-intensity therapy for patients with multiple myeloma.

Dr. Silbermann on the Role of Disease Biology in Multiple Myeloma

October 13th 2020

Rebecca Silbermann, MD, MMS, discusses the role of disease biology in multiple myeloma.